HomeInvestingPortfolio ManagementEli Lilly (LLY) Drug Gets FDA Approval, Up 10% YTD
Eli Lilly (LLY) Drug Gets FDA Approval, Up 10% YTD

The FDA approves an Eli Lilly (LLY) cancer drug, Retevmo, for new uses. George Tsilis discusses LLY as UBS upgraded LLY to buy from neutral and raised its price target to $363. He talks about how LLY hit 52-week high on July 15th and is up over 10% YTD. He then goes over how LLY, as well as other Pharma stocks have been and continue to be recession resistant. He then demonstrates an example trade using LLY. Tune in to find out more about the stock market today.

Trading 360

22 Sep 2022

ON AIR
11:00 pm
Trading 360
replay
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
education
3:30 pm
Your First Trade
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
education
7:00 pm
Your First Trade
REPLAY
7:30 pm
Trading 360
REPLAY
8:30 pm
Fast Market
REPLAY
9:30 pm
Next Gen Investing
REPLAY
education
10:30 pm
Your First Trade
REPLAY
ON AIR
11:00 pm
Trading 360
REPLAY

Get Market Minute

Daily insights for every investor

FOLLOW US